Silverfin false false 31/12/2025 01/01/2025 31/12/2025 M I Hill 19/06/2018 I Urnes 20/12/2017 24 August 2026 no description of principal activity 11119894 2025-12-31 11119894 bus:Director1 2025-12-31 11119894 bus:Director2 2025-12-31 11119894 2024-12-31 11119894 core:CurrentFinancialInstruments 2025-12-31 11119894 core:CurrentFinancialInstruments 2024-12-31 11119894 core:Non-currentFinancialInstruments 2025-12-31 11119894 core:Non-currentFinancialInstruments 2024-12-31 11119894 core:ShareCapital 2025-12-31 11119894 core:ShareCapital 2024-12-31 11119894 core:SharePremium 2025-12-31 11119894 core:SharePremium 2024-12-31 11119894 core:RetainedEarningsAccumulatedLosses 2025-12-31 11119894 core:RetainedEarningsAccumulatedLosses 2024-12-31 11119894 core:OtherResidualIntangibleAssets 2024-12-31 11119894 core:OtherResidualIntangibleAssets 2025-12-31 11119894 core:OfficeEquipment 2024-12-31 11119894 core:ComputerEquipment 2024-12-31 11119894 core:OfficeEquipment 2025-12-31 11119894 core:ComputerEquipment 2025-12-31 11119894 core:CostValuation 2024-12-31 11119894 core:CostValuation 2025-12-31 11119894 2023-12-31 11119894 bus:OrdinaryShareClass1 2025-12-31 11119894 2025-01-01 2025-12-31 11119894 bus:FilletedAccounts 2025-01-01 2025-12-31 11119894 bus:SmallEntities 2025-01-01 2025-12-31 11119894 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 11119894 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 11119894 bus:Director1 2025-01-01 2025-12-31 11119894 bus:Director2 2025-01-01 2025-12-31 11119894 core:OtherResidualIntangibleAssets core:TopRangeValue 2025-01-01 2025-12-31 11119894 core:OfficeEquipment core:TopRangeValue 2025-01-01 2025-12-31 11119894 core:ComputerEquipment core:TopRangeValue 2025-01-01 2025-12-31 11119894 2024-01-01 2024-12-31 11119894 core:OtherResidualIntangibleAssets 2025-01-01 2025-12-31 11119894 core:OfficeEquipment 2025-01-01 2025-12-31 11119894 core:ComputerEquipment 2025-01-01 2025-12-31 11119894 core:Non-currentFinancialInstruments 2025-01-01 2025-12-31 11119894 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 11119894 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 11119894 (England and Wales)

GENERATED HEALTH LTD

Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

GENERATED HEALTH LTD

Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

GENERATED HEALTH LTD

COMPANY INFORMATION

For the financial year ended 31 December 2025
GENERATED HEALTH LTD

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2025
Directors M I Hill
I Urnes
Registered office Mercury House
117 Waterloo Road
London
SE1 8UL
United Kingdom
Company number 11119894 (England and Wales)
Accountant Kreston Reeves LLP
Suite 2
Orchard House
Orchard Street
Canterbury
Kent
CT2 8AR

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF
THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF GENERATED HEALTH LTD

For the financial year ended 31 December 2025

ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF
THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF GENERATED HEALTH LTD (continued)

For the financial year ended 31 December 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Generated Health Ltd for the financial year ended 31 December 2025 which comprise the Balance Sheet and the related notes 1 to 12 from the Company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/regulation.

This report is made solely to the Board of Directors of Generated Health Ltd, as a body, in accordance with the terms of our engagement letter dated 21 January 2026. Our work has been undertaken solely to prepare for your approval the financial statements of Generated Health Ltd and state those matters that we have agreed to state to the Board of Directors of Generated Health Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Generated Health Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Generated Health Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Generated Health Ltd. You consider that Generated Health Ltd is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the financial statements of Generated Health Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Kreston Reeves LLP

Suite 2
Orchard House
Orchard Street
Canterbury
Kent
CT2 8AR

25 August 2026

GENERATED HEALTH LTD

BALANCE SHEET

As at 31 December 2025
GENERATED HEALTH LTD

BALANCE SHEET (continued)

As at 31 December 2025
Note 2025 2024
£ £
Fixed assets
Intangible assets 3 212,917 244,900
Tangible assets 4 5,587 1,207
Investments 5 68,882 68,882
287,386 314,989
Current assets
Debtors
- due within one year 6 2,787,886 1,994,847
- due after more than one year 6 2,531,991 1,059,551
Cash at bank and in hand 20,983 5,083
5,340,860 3,059,481
Creditors: amounts falling due within one year 7 ( 105,021) ( 107,675)
Net current assets 5,235,839 2,951,806
Total assets less current liabilities 5,523,225 3,266,795
Creditors: amounts falling due after more than one year 8 ( 4,004,990) ( 1,656,269)
Net assets 1,518,235 1,610,526
Capital and reserves
Called-up share capital 10 601 601
Share premium account 11 4,174,977 4,174,977
Profit and loss account ( 2,657,343 ) ( 2,565,052 )
Total shareholder's funds 1,518,235 1,610,526

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Generated Health Ltd (registered number: 11119894) were approved and authorised for issue by the Board of Directors on 24 August 2026. They were signed on its behalf by:

I Urnes
Director
GENERATED HEALTH LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
GENERATED HEALTH LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Generated Health Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Mercury House, 117 Waterloo Road, London, SE1 8UL, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet at the date of approving these financial statements. The directors have a reasonable expectation that the Company has continued support from the wider group companies to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Income Statement in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Income Statement in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Other intangible assets 10 years straight line
Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Office equipment 4 years straight line
Computer equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including directors 14 12

3. Intangible assets

Other intangible assets Total
£ £
Cost
At 01 January 2025 317,835 317,835
At 31 December 2025 317,835 317,835
Accumulated amortisation
At 01 January 2025 72,935 72,935
Charge for the financial year 31,983 31,983
At 31 December 2025 104,918 104,918
Net book value
At 31 December 2025 212,917 212,917
At 31 December 2024 244,900 244,900

4. Tangible assets

Office equipment Computer equipment Total
£ £ £
Cost
At 01 January 2025 630 12,279 12,909
Additions 0 5,967 5,967
At 31 December 2025 630 18,246 18,876
Accumulated depreciation
At 01 January 2025 628 11,074 11,702
Charge for the financial year 2 1,585 1,587
At 31 December 2025 630 12,659 13,289
Net book value
At 31 December 2025 0 5,587 5,587
At 31 December 2024 2 1,205 1,207

5. Fixed asset investments

Investments in subsidiaries

2025
£
Cost
At 01 January 2025 68,882
At 31 December 2025 68,882
Carrying value at 31 December 2025 68,882
Carrying value at 31 December 2024 68,882

6. Debtors

2025 2024
£ £
Debtors: amounts falling due within one year
Trade debtors 2,680,062 1,907,159
Other debtors 107,824 87,688
2,787,886 1,994,847
Debtors: amounts falling due after more than one year
Amounts owed by Group undertakings 2,531,991 1,059,551

7. Creditors: amounts falling due within one year

2025 2024
£ £
Trade creditors 11,849 17,041
Other taxation and social security 34,854 33,671
Other creditors 58,318 56,963
105,021 107,675

8. Creditors: amounts falling due after more than one year

2025 2024
£ £
Amounts owed to Group undertakings 3,806,990 1,422,269
Obligations under finance leases and hire purchase contracts 198,000 234,000
4,004,990 1,656,269

There are no amounts included above in respect of which any security has been given by the company.

9. Deferred tax

2025 2024
£ £
At the beginning of financial year 0 0
Charged to the Income Statement ( 1,061) 0
At the end of financial year ( 1,061) 0

10. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
600,857 Ordinary shares of £ 0.001 each 601 601

11. Share Premium Account

This reserve records the amounts above the nominal value received for shares issued by the company. Share premium may only be utilised to write off any expenses incurred or commissions paid on the issue of those shares, or to pay up new shares to be allotted to members as fully paid bonus shares.

12. Ultimate controlling party

The ultimate controlling party is Generated Health Inc by virtue of its 100% holding in the issued share capital and voting rights in the company.